Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the FDA for the treatment of non-metastatic castration-resistant prostate cancer that continues to grow despite the administration of hormone therapy, just a week after it made public strong new data in the same indication.
J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup
